10baggerbamm :
no matter what time frame of a chart you pull up daily weekly monthly yearly it's a complete disaster. 10 years of wealth destroyed since covid.
1.$Annovis Bio(ANVS.US)$ • Ph 3 data (also Ph 2/3 in AD). • Buntanetap for Parkinson’s Disease. • Exp Jan '24 but delayed (est this qtr). 2.$Axsome Therapeutics(AXSM.US)$ • Ph 3 data (SYMPHONY). • AXS-12 for Narcolepsy. • AXS-12 has Orphan Drug Designation. 3.$G1 Therapeutics(GTHX.US)$ • Ph 3 Overall Survival (OS) data. • Trilaciclib (combo) for breast cancer (mTNBC). • DMC recommended continuation earlier in Feb. 4.$Crinetics(CRNX.US)$ • Ph 3 data (PATHFND...
$Crinetics(CRNX.US)$Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome 1 MINUTE AGO, 4:05 PM EST VIA GLOBENEWSWIRE
JP Morgan predicts growth for Insmed due to recent study updates, potential rise of Denali shares ahead of 2025 readouts, and an upside for Immunocore shares following a 'strong' oncology drug launch. Crinetics could also benefit from upcoming catalysts.
10baggerbamm : no matter what time frame of a chart you pull up daily weekly monthly yearly it's a complete disaster. 10 years of wealth destroyed since covid.